Amarin – an overnight success 10 years in the making
After several false starts, way is clear for John Thero to take Vascepa cholesterol drug to market
Amarin reports 62% rise in fourth quarter sales of Vascepa
Costs, including ongoing R&D, means the company reports loss of $21.9 million for the quarter and $115.2 million for full year
Amarin shares slump on FDA panel rejection
Company fails to persuade advisory panel to back exponential expansion of market for cardiovascular drug
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Stardust
Inquests into the nightclub fire that led to the deaths of 48 people
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices